Winai Porntipworawech: The $50 Life-Saving Drug Big Pharma Doesn’t Want You to See
Winai Porntipworawech, Former Vice President of GCME, shared a post on LinkedIn:
“Brazilian scientists at Butantan Institute developed a snake venom-derived drug that dissolves dangerous blood clots within minutes without major side effects.
The medication costs $50 per treatment compared to American alternatives charging more than $5,000 with significant bleeding risks.
The drug uses a modified protein from Brazilian pit viper venom that specifically targets clot-forming proteins.
Unlike American blood thinners that affect entire clotting systems, this medication only dissolves existing dangerous clots.
Patients avoid the bleeding complications that kill thousands yearly from traditional treatments.
It works like targeted demolition rather than carpet bombing.
The pharmaceutical industry resistance reveals priorities.
American drug companies promote expensive blood thinners despite high complication rates and limited effectiveness.
The cheap Brazilian alternative threatens $30 billion in yearly American anticoagulant sales.
Critics argue industry lobbying delays FDA approval despite proven safety in extensive Brazilian trials.
For 795,000 Americans suffering strokes yearly and millions taking blood thinners, this represents lifesaving innovation kept inaccessible.
The current American treatment causes 1 in 100 patients to suffer dangerous bleeding episodes.
Brazilian alternatives prevent both clots and complications while costing 100 times less than American medications.
Should American patients suffer dangerous side effects when Brazilian alternatives prove safer and cheaper?
Source: Butantan Institute and New England Journal of Medicine, February 2025.”

Stay updated with Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?